The abstract is read at the publisher; the summary is JClub's.
In adults with heart failure and left ventricular ejection fraction ≤40% in the POLY-HF randomized trial, a once-daily polypill improved ejection fraction by 3.3 percentage points at 6 months.
- Why it matters: Guideline-directed medical therapy improves outcomes, but real-world use is low; this trial tests whether simplifying treatment can improve cardiac function in a predominantly underserved population.
- What they did: POLY-HF was an open-label randomized trial at two centers enrolling 212 adults, comparing a polypill (metoprolol succinate, spironolactone, empagliflozin) plus separate renin-angiotensin therapy versus enhanced usual care with rapid uptitration.
- The result: Among 187 participants with 6-month cardiac magnetic resonance imaging, polypill treatment also reduced heart failure hospitalizations or emergency visits (adjusted rate ratio 0.40) and improved adherence (79% vs 54%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.